logo-loader
viewCB2 Insights Inc.

Cb2 Insights signs letter of Intent with UK company, Drug Science for research program TWENTY21

CB2 Insights (CSE: CBII-OTCQB: CBIIT) CEO Prad Sekar joined Steve Darling on Skype from London with news the company has been selected as an exclusive research technology platform for the UK’s largest medical cannabis Pilot – Project TWENTY21

Sekar told Proactive about that project and how CB2 will be involved.

 

Quick facts: CB2 Insights Inc.

Price: 0.1 CAD

CSE:CBII
Market: CSE
Market Cap: $8 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CB2 Insights Inc. named herein, including the promotion by the Company of CB2 Insights Inc. in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: CB2 Insights partners with fully licensed Colombia-based...

CB2 Insights Inc (CSE:CBII) (OTCQB:CBIIF) CEO Prad Sekar tells Proactive that the Ontario-based company is partnering with licensed producer FCM Global S.A.S. Sekar says FCM Global is one of the only fully licensed Colombian cannabis producers where CB2 will support its medical cannabis...

1 week, 3 days ago

2 min read